Literature DB >> 11260814

Subjective and discriminative stimulus effects of two de-nicotinized cigarettes with different tar yields.

L M Schuh1, H M Stamat, K K Downey, K J Schuh.   

Abstract

The role of tar yield in the subjective and discriminative stimulus effects of cigarette smoking was examined. Current smokers (n=18) smoked two non-nicotine cigarettes with FTC yields of 0.06 mg nicotine and 12.4 mg (low tar) or 17.9 mg tar (high tar). Physiological measures and visual analog scales were completed over a 30-min period. Dosing order was determined randomly and counterbalanced. After sampling both cigarettes, volunteers smoked a third, test cigarette. Half of the volunteers received the low-tar cigarette and half the high-tar cigarette. Volunteers identified the test cigarette (i.e., A or B) at 5, 30, 60, 300, and 900 s after the first puff. Eight of the eighteen participants correctly identified the test cigarette on 4/5 of trials. No significant changes in visual analog scale scores were found among the non-discriminators. However, among discriminators, the low-tar cigarette produced significant positive effects including good drug effects and stimulation relative to the high-tar cigarette. Relative to the low-tar cigarette, the high-tar cigarette produced negative effects including harshness, heaviness, and intensity of flavor. Average tar yield of these participants' usual cigarettes was 9.75 mg, lower than that of the low-tar cigarette used here, possibly accounting for their greater liking of the low-tar cigarette. No changes in blood pressure or heart rate were observed and both cigarettes produced similar carbon monoxide increases, indicating similar depth of inhalation when smoking each. Results suggest cigarette tar yields may play a role in cigarette smoking preferences. Further research is needed to verify whether preferences are maintained after associations with nicotine delivery are extinguished.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11260814     DOI: 10.1080/14622200020032123

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  6 in total

Review 1.  Measures for assessing subjective effects of potential reduced-exposure products.

Authors:  Karen Hanson; Richard O'Connor; Dorothy Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

2.  Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge.

Authors:  Michael Kotlyar; M Irene Mendoza-Baumgart; Zhong-ze Li; Paul R Pentel; Brianne C Barnett; Rachel M Feuer; Erin A Smith; Dorothy K Hatsukami
Journal:  Tob Control       Date:  2007-04       Impact factor: 7.552

3.  Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette.

Authors:  Arthur L Brody; Mark A Mandelkern; Richard E Olmstead; Zoe Allen-Martinez; David Scheibal; Anna L Abrams; Matthew R Costello; Judah Farahi; Sanjaya Saxena; John Monterosso; Edythe D London
Journal:  Neuropsychopharmacology       Date:  2008-06-18       Impact factor: 7.853

Review 4.  Assessing consumer responses to potential reduced-exposure tobacco products: a review of tobacco industry and independent research methods.

Authors:  Vaughan W Rees; Jennifer M Kreslake; K Michael Cummings; Richard J O'Connor; Dorothy K Hatsukami; Mark Parascandola; Peter G Shields; Gregory N Connolly
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 5.  Clinical trials methods for evaluation of potential reduced exposure products.

Authors:  Dorothy K Hatsukami; Karen Hanson; Anna Briggs; Mark Parascandola; Jeanine M Genkinger; Richard O'Connor; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

6.  Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette.

Authors:  Arthur L Brody; Mark A Mandelkern; Matthew R Costello; Anna L Abrams; David Scheibal; Judah Farahi; Edythe D London; Richard E Olmstead; Jed E Rose; Alexey G Mukhin
Journal:  Int J Neuropsychopharmacol       Date:  2008-08-18       Impact factor: 5.176

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.